← 홈

Catalyst · Landscape

향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS

파이프라인 Phase 분포

큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.

Preclinical
132
Phase 1
491
Phase 2
979
Phase 3
293
Approved
134

Catalyst target · modality

향후 6개월 catalyst 9건 · 타깃·모달리티 분포

Antibody 9
CD38
5
Chronic
1
BCMA
1
FRα
1
Multiple
1

향후 6개월 Catalyst(9 / 80)

활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시

완료 예정프로그램PhaseStatusEndpoint신뢰도NCT
2026년 9월TocilizumabAntibody · Chronic Lymphocytic LeukemiaPhase 3Active, not recruitingmodified Rankin Scale (mRS) score at 90 days신뢰 높음NCT07263776
2026년 9월Tecvayli (teclistamab)Antibody · BCMA × CD3N/ANot yet recruitingPain perception during local anesthetic injection보통NCT07124052
2026년 9월TalquetamabAntibody · FRα—RecruitingDescribe Baseline Characteristics of Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who Received Teclistamab/ Talquetamab Outside of Clinical Trials; Overall Response Rate (ORR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to First Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to Best Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Duration of Response (DOR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Minimal Residue Assessment (MRD) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Overall Survival (OS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Progression Free Survival (PFS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to Next Treatment (TTNT) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Describe the Safety Management of Teclistamab/Talquetamab in the Treatment of Participants with RRMM Outside of Clinical Trials신뢰 높음NCT06285318
2026년 9월Darzalex (daratumumab)Antibody · CD38Phase 2Active, not recruitingEfficacy of daratumumab in inducing complete(CR) or partial(PR) renal remission in patients with active class III or IV Lupus Nephritis; Efficacy of daratumumab in inducing complete(CR) or partial(PR)보통NCT04868838
2026년 9월Darzalex (daratumumab)Antibody · CD38Phase 1, Phase 2RecruitingNumber of Participants with Dose Limiting Toxicities (DLT) (Phase 1); Hematologic ≥ Very Good Partial Response (VGPR) Rate (Phase 2)신뢰 높음NCT05451771
2026년 9월IsatuximabAntibody · Multiple MyelomaPhase 2Active, not recruitingMRD negativity신뢰 높음NCT03104842
2026년 9월Darzalex (daratumumab)Antibody · CD38Phase 1Active, not recruitingNumber of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0보통NCT07042594
2026년 9월Darzalex (daratumumab)Antibody · CD38Phase 2Active, not recruitingBest Overall Response신뢰 높음NCT03290950
2026년 9월Darzalex (daratumumab)Antibody · CD38Phase 2Active, not recruitingDeep clinical response신뢰 높음NCT06169215
  • 2026년 9월신뢰 높음
    Tocilizumab

    Antibody · Chronic Lymphocytic Leukemia · Phase 3

    modified Rankin Scale (mRS) score at 90 days

    NCT07263776
  • 2026년 9월보통
    Tecvayli (teclistamab)

    Antibody · BCMA × CD3 · N/A

    Pain perception during local anesthetic injection

    NCT07124052
  • 2026년 9월신뢰 높음
    Talquetamab

    Antibody · FRα · —

    Describe Baseline Characteristics of Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who Received Teclistamab/ Talquetamab Outside of Clinical Trials; Overall Response Rate (ORR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to First Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to Best Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Duration of Response (DOR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Minimal Residue Assessment (MRD) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Overall Survival (OS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Progression Free Survival (PFS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to Next Treatment (TTNT) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Describe the Safety Management of Teclistamab/Talquetamab in the Treatment of Participants with RRMM Outside of Clinical Trials

    NCT06285318
  • 2026년 9월보통
    Darzalex (daratumumab)

    Antibody · CD38 · Phase 2

    Efficacy of daratumumab in inducing complete(CR) or partial(PR) renal remission in patients with active class III or IV Lupus Nephritis; Efficacy of daratumumab in inducing complete(CR) or partial(PR)

    NCT04868838
  • 2026년 9월신뢰 높음
    Darzalex (daratumumab)

    Antibody · CD38 · Phase 1, Phase 2

    Number of Participants with Dose Limiting Toxicities (DLT) (Phase 1); Hematologic ≥ Very Good Partial Response (VGPR) Rate (Phase 2)

    NCT05451771
  • 2026년 9월신뢰 높음
    Isatuximab

    Antibody · Multiple Myeloma · Phase 2

    MRD negativity

    NCT03104842
  • 2026년 9월보통
    Darzalex (daratumumab)

    Antibody · CD38 · Phase 1

    Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0

    NCT07042594
  • 2026년 9월신뢰 높음
    Darzalex (daratumumab)

    Antibody · CD38 · Phase 2

    Best Overall Response

    NCT03290950
  • 2026년 9월신뢰 높음
    Darzalex (daratumumab)

    Antibody · CD38 · Phase 2

    Deep clinical response

    NCT06169215